MPN Cancer Connection

10/24/2025

MPN-BP transformation is driven by sequential mutations disrupting genomic stability, with TP53 mutations being strong predictors of progression.

Dana-Farber researchers have uncovered mutation pathways driving aggressive disease transformation.

10/12/2025

Explore how interferon therapy helps treat MPNs like PV, ET, and early MF. Learn about its benefits, side effects, and why it’s ideal for younger patients.

09/19/2025

Joseph Scandura, MD, PhD, Weill Cornell Medicine, New York, comments on the risk of pulmonary hypertension in patients with polycythemia vera (PV) and highlights the impact of this complication on survival outcomes.

Joseph Scandura, MD, PhD, Weill Cornell Medicine, New York, NY, comments on the risk of pulmonary hypertension in patients with polycythemia vera (PV) and hi...

09/17/2025

🚨 Attention MPN Patients!
The PAN Foundation grant is OPEN ✅ Annual max: $9,500

📊 Income limits (500% FPL):
👤 1 person: $78,250
👥 2 people: $105,750
👨‍👩‍👧 3 people: $133,250
👨‍👩‍👧‍👦 4 people: $160,750

👉 Apply now: PAN Grant Application
📞 Or call: 1-866-316-7263

💡 Don’t wait—funds are limited!

Learn about applying for grants online or by phone, how to prepare your application, and what to do after you apply.

09/10/2025

🌍 MPN Awareness Day – September 11, 2025

MPNs are rare blood cancers, but together we can shine a light and support those living with them.

💬 “The human spirit is stronger than anything that can happen to it.” – C.C. Scott

🔗 More info: https://www.pvreporter.com

09/04/2025

🩸 September is Blood Cancer Awareness Month

This cartoon shows red blood cells “gone wild,” a playful way to highlight a serious condition: Polycythemia Vera (PV).

In PV, the bone marrow produces too many red blood cells, and sometimes platelets and white blood cells. This can thicken the blood while raising the risk of clots, strokes, or other dangerous complications.

👉 Learn more and find trusted resources: https://www.pvreporter.com/

Feel free to share this post with your network.

09/01/2025

🎗 September is Blood Cancer Awareness Month
MPNs are rare blood cancers:

Polycythemia Vera (PV)

Essential Thrombocythemia (ET)

Myelofibrosis (MF)

Learn more & help raise awareness:
👉 https://www.pvreporter.com/september-blood-cancer-awareness-month-mpns/

❤️ Please share to support patients & families.

Blood Cancer Awareness Month is September. Help us continue to raise awareness, MPN Awareness Day is September 12th, 2024.

08/26/2025

ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis

ADORE was an open platform study of 5 ruxolitinib combinations in patients with MF and suboptimal response to ruxolitinib alone. Most patients received the siremadlin combination; there were no new safety signals and siremadlin 30 mg demonstrated ...

08/23/2025

The monoclonal antibody INCA44989 is the first-ever treatment for essential thrombocythemia (ET) that may alter the underlying mechanism of disease for patients with mutations of calreticulin (mutCALR), according to a recent phase 1 study. The majority of patients achieved a swift and durable response.

Phase 1 study found mutant calreticulin-specific monoclonal antibody brings promising results with no dose-limiting toxicities

08/22/2025

Considerations for Selection and Sequencing in Polycythemia Vera and Myelofibrosis

Naseema Gangat, MBBS, delves into the role of ruxolitinib as a standard of care for the treatment of patients with polycythemia vera and myelofibrosis.